1. Home
  2. LTRX vs IMUX Comparison

LTRX vs IMUX Comparison

Compare LTRX & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lantronix Inc.

LTRX

Lantronix Inc.

N/A

Current Price

$5.64

Market Cap

199.5M

ML Signal

N/A

Logo Immunic Inc.

IMUX

Immunic Inc.

N/A

Current Price

$0.57

Market Cap

85.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LTRX
IMUX
Founded
1989
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Communications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
199.5M
85.8M
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
LTRX
IMUX
Price
$5.64
$0.57
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
$6.17
$6.00
AVG Volume (30 Days)
463.3K
1.4M
Earning Date
02-05-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$118,294,000.00
N/A
Revenue This Year
$4.59
N/A
Revenue Next Year
$12.20
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.91
$0.55
52 Week High
$6.75
$1.39

Technical Indicators

Market Signals
Indicator
LTRX
IMUX
Relative Strength Index (RSI) 55.17 35.53
Support Level $5.54 $0.55
Resistance Level $5.93 $0.65
Average True Range (ATR) 0.38 0.04
MACD -0.04 -0.00
Stochastic Oscillator 43.49 14.66

Price Performance

Historical Comparison
LTRX
IMUX

About LTRX Lantronix Inc.

Lantronix Inc is a networking company. It provides secure data access and management solutions for the Internet of Things (IoT) and information technology assets. It organizes its products and solutions into three product lines: Embedded IoT Solutions, IoT Systems Solutions, and Software and Services. The IoT System Solutions segment is the key revenue driver for the company. The company serves a diverse range of markets including healthcare, industrial, security, energy, transportation, and government networking. Its primary geographic markets are the Americas, Europe, the Middle East and Africa, and Asia Pacific Japan. The Americas contribute the vast majority of total revenue.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Share on Social Networks: